Patents by Inventor Julia L. Greenstein
Julia L. Greenstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100209449Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: April 23, 2010Publication date: August 19, 2010Inventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter
-
Publication number: 20100105672Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: August 3, 2009Publication date: April 29, 2010Inventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers
-
Publication number: 20100068222Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: August 3, 2009Publication date: March 18, 2010Inventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers
-
Patent number: 7482008Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.Type: GrantFiled: September 15, 2000Date of Patent: January 27, 2009Assignee: Merck Patent GmbHInventors: Malcolm L. Gefter, Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Irwin J. Griffith, Jay P. Morgenstern, Julian F. Bond, Andrew W. Brauer, Malcolm Morville, Thomas J. Briner, Ze'ev Shaked
-
Patent number: 7288256Abstract: The present invention provides isolated peptides of the major protein allergens of the genus Dermatophagoides. Peptides within the scope of the invention comprises at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen selected from the allergens Der p I, Der p II, Der f I, or Der f II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or of diagnosis of sensitivity to house dust mites in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.Type: GrantFiled: May 19, 1995Date of Patent: October 30, 2007Assignee: Merck Patent GmbHInventors: Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Henry M. Franzen, Xian Chen, Sean Evans, Ze'ev Shaked
-
Patent number: 7211408Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.Type: GrantFiled: June 16, 2003Date of Patent: May 1, 2007Assignee: Merck Patent GmbHInventors: Bruce L. Rogers, Jay P. Morgenstern, Julian F. Bond, Richard D. Garman, Julia L. Greenstein, Mei-Chang Kuo, Malcolm Morville
-
Publication number: 20040057959Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.Type: ApplicationFiled: June 16, 2003Publication date: March 25, 2004Inventors: Bruce L. Rogers, Jay P. Morgenstern, Julian F. Bond, Richard D. Garman, Julia L. Greenstein, Mei-Chang Kuo, Malcolm Morville
-
Publication number: 20030069400Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: April 1, 2002Publication date: April 10, 2003Applicant: Xenova Research LimitedInventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter
-
Publication number: 20030035815Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.Type: ApplicationFiled: June 5, 1995Publication date: February 20, 2003Inventors: BRUCE L. ROGERS, JAY P. MORGENSTERN, JULIAN F. BOND, RICHARD D. GARMAN, JULIA L. GREENSTEIN, MEI-CHANG KUO, MALCOLM MORVILLE
-
Publication number: 20020032316Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: June 14, 2001Publication date: March 14, 2002Applicant: Cantab Pharmaceuticals Research LimitedInventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter
-
Patent number: 6268491Abstract: The present invention provides isolated peptides of the major protein allergens of the genus Dermatophagoides. Peptides within the scope of the invention comprises at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen selected from the allergens Der p I, Der p II, Der f I, or Der f II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or of diagnosis of sensitivity to house dust mites in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.Type: GrantFiled: June 7, 1995Date of Patent: July 31, 2001Assignee: ImmuLogic Pharmaceutical CorporationInventors: Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Henry M. Franzen, Xian Chen, Sean Evans, Ze′ev Shaked
-
Patent number: 6120769Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.Type: GrantFiled: April 28, 1995Date of Patent: September 19, 2000Assignee: ImmuLogic Pharmaceutical CorporationInventors: Malcolm L. Gefter, Richard D. Garman, Julia L. Greenstein, Julian F. Bond
-
Patent number: 6054127Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: GrantFiled: June 27, 1997Date of Patent: April 25, 2000Assignee: Immulogic Pharmaceutical CorporationInventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter, Thomas J. Briner
-
Patent number: 6048962Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.Type: GrantFiled: April 27, 1995Date of Patent: April 11, 2000Assignee: Immulogic Pharmaceutical CorporationInventors: Malcolm L. Gefter, Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Irwin J. Griffith, Jay P. Morgenstern, Andrew W. Brauer
-
Patent number: 6019972Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.Type: GrantFiled: September 2, 1994Date of Patent: February 1, 2000Assignee: ImmuLogic Pharmaceutical CorporationInventors: Malcolm L. Gefter, Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Malcolm Morville, Thomas J. Briner
-
Patent number: 5968526Abstract: The present invention provides isolated peptides of the major protein allergens of the genus Dermatophagoides. Peptides within the scope of the invention comprises at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen selected from the allergens Der p I, Der p II, Der f I, or Der f II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or of diagnosis of sensitivity to house dust mites in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.Type: GrantFiled: June 7, 1995Date of Patent: October 19, 1999Assignee: Immulogic Pharamaceutical CorporationInventors: Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Henry M. Franzen, Xian Chen, Sean Evans, Ze'ev Shaked
-
Patent number: 5876727Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: GrantFiled: September 30, 1996Date of Patent: March 2, 1999Assignee: ImmuLogic Pharmaceutical CorporationInventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter
-
Patent number: 5820862Abstract: The present invention provides isolated peptides of the major protein allergens of the genus Dermatophagoides. Peptides within the scope of the invention comprises at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen selected from the allergens Der p I, Der p II, Der f I, or Der f II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or of diagnosis of sensitivity to house dust mites in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.Type: GrantFiled: June 7, 1995Date of Patent: October 13, 1998Assignee: Immulogic Pharmaceutical CorporationInventors: Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Henry M. Franzen, Xian Chen, Sean Evans, Ze'ev Shaked
-
Patent number: 5760184Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: GrantFiled: November 28, 1995Date of Patent: June 2, 1998Assignee: ImmuLogic, Inc.Inventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter, Thomas J. Briner
-
Patent number: 5547669Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.Type: GrantFiled: December 13, 1991Date of Patent: August 20, 1996Inventors: Bruce L. Rogers, Jay P. Morgenstern, Julian F. Bond, Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Malcolm Morville